Lifespan Based Pharmacokinetic-Pharmacodynamic Model of Tumor Growth Inhibition by Anticancer Therapeutics

被引：0
|
作者：
Mo, Gary [1 ]
Gibbons, Frank [2 ]
Schroeder, Patricia [2 ]
Krzyzanski, Wojciech [1 ]
机构：
[1] SUNY Buffalo, Buffalo, NY 14260 USA
[2] AstraZeneca R&D Boston, Waltham, MA USA
来源：
JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS | 2013年 / 40卷
关键词：
EFFICACY;
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
引用
收藏
页码：S56 / S57
页数：2
相关论文
共 50 条
  • [31] An integrated pharmacokinetic-pharmacodynamic model for an Aurora kinase inhibitor
    Kamei, Hiroko
    Jackson, Robert C.
    Zheleva, Daniella
    Davidson, Fordyce A.
    JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS, 2010, 37 (04) : 407 - 434
  • [32] A population pharmacokinetic-pharmacodynamic analysis and model validation of azimilide
    Phillips, L
    Grasela, TH
    Agnew, JR
    Ludwig, EA
    Thompson, GA
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2001, 70 (04) : 370 - 383
  • [33] A pharmacokinetic-pharmacodynamic model for individualisation of an oral anticoagulation therapy
    Ferrari, Myriam
    Bosa, Luigi
    De-Luca, Riccardo
    Barolo, Massimiliano
    Zambon, Carlo F.
    Pengo, Vittorio
    Padrini, Roberto
    Bezzo, Fabrizio
    26TH EUROPEAN SYMPOSIUM ON COMPUTER AIDED PROCESS ENGINEERING (ESCAPE), PT B, 2016, 38B : 2313 - 2318
  • [34] Pharmacokinetic-Pharmacodynamic Model for the Reversal of Neuromuscular Blockade by Sugammadex
    Ploeger, Batt A.
    Smeets, Jean
    Strougo, Ashley
    Drenth, Henk-Jan
    Ruigt, Ge
    Houwing, Natalie
    Danhof, Meindert
    ANESTHESIOLOGY, 2009, 110 (01) : 95 - 105
  • [35] A pharmacokinetic-pharmacodynamic model for chemoprotective agents against malaria
    Cherkaoui-Rbati, Mohammed H.
    Andenmatten, Nicole
    Burgert, Lydia
    Egbelowo, Oluwaseun F.
    Fendel, Rolf
    Fornari, Chiara
    Gabel, Michael
    Ward, John
    Mohrle, Jorg J.
    Gobeau, Nathalie
    CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY, 2023, 12 (01): : 50 - 61
  • [36] Development of a pharmacokinetic-pharmacodynamic model of inolimomab in GVHD patients
    Girard, P.
    Dartois, C.
    Michallet, M.
    Henin, E.
    Vermot-Desroches, C.
    Tranchand, B.
    Trillet-Lenoir, V
    Freyer, G.
    BULLETIN DU CANCER, 2008, 95 : S74 - S74
  • [37] A Population Pharmacokinetic-Pharmacodynamic Model for Allopurinol in Patients with Gout
    Wright, Daniel F. B.
    Duffull, Stephen B.
    Merriman, Tony R.
    Barclay, Murray L.
    Stamp, Lisa K.
    JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS, 2014, 41 : S33 - S33
  • [38] Atazanavir-bilirubin interaction: a pharmacokinetic-pharmacodynamic model
    Lozano, Roberto
    Domeque, Nieves
    Apesteguia, Alberto-Fermin
    CLINICAL PHARMACOLOGY-ADVANCES AND APPLICATIONS, 2013, 5 : 153 - 159
  • [39] Pharmacokinetic-pharmacodynamic modeling of biomarker response and tumor growth inhibition to an orally available cMet kinase inhibitor in human tumor xenograft mouse models
    Yamazaki, Shinji
    Skaptason, Judith
    Romero, David
    Lee, Joseph H.
    Zou, Helen Y.
    Christensen, James G.
    Koup, Jeffrey R.
    Smith, Bill J.
    Koudriakova, Tatiana
    DRUG METABOLISM AND DISPOSITION, 2008, 36 (07) : 1267 - 1274
  • [40] TRANSLATIONAL PHARMACOKINETIC/PHARMACODYNAMIC MODEL PREDICTS DEPATUXIZUMAB MAFODOTIN TUMOR GROWTH INHIBITION IN PATIENTS.
    Mittapalli, R. K.
    Chiney, M. S.
    Shebley, M.
    Gibbs, J. P.
    Xiong, H.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2018, 103 : S80 - S80
12345